Call us : (250) 377-1182
facebook twitter linked-in
opawica ntg fairmount lingo media lux

BioMS Medical (MS-T)



Hello there guest! Want to join in on the conversation? Login or register for a forums account by visiting this link.


By analyst8

Posted: Friday Apr 4 2:08:38PM 2008

More insider buying and company buying back shares: BioMS Medical Corp. (MS) As of April 3rd, 2008 Filing Date Transaction Date Insider Name Ownership Type Securities Nature of transaction # or value acquired or disposed of Unit Price Apr 02/08 Apr 01/08 Kimak, Donald William Direct Ownership Common Shares Class A 10 - Acquisition in the public market 4,000 $3.750 Apr 01/08 Mar 31/08 Kimak, Donald William Direct Ownership Common Shares Class A 10 - Acquisition in the public market 5,000 $3.730 Apr 01/08 Mar 25/08 BioMS Medical Corp. Direct Ownership Common Shares Class A 38 - Redemption, retraction, cancellation, repurchase 600 $3.390 Mar 27/08 Mar 24/08 Kimak, Donald William Direct Ownership Common Shares Class A 10 - Acquisition in the public market 1,200 $3.400 Mar 27/08 Mar 24/08 BioMS Medical Corp. Direct Ownership Common Shares Class A 38 - Redemption, retraction, cancellation, repurchase 1,200 $3.390 Mar 27/08 Mar 26/08 BioMS Medical Corp. Direct Ownership Common Shares Class A 38 - Redemption, retraction, cancellation, repurchase -8,000 Feb 07/08 Feb 06/08 BioMS Medical Corp. Direct Ownership Common Shares Class A 38 - Redemption, retraction, cancellation, repurchase 1,000 $3.600 Feb 04/08 Feb 01/08 BioMS Medical Corp. Direct Ownership Common Shares Class A 38 - Redemption, retraction, cancellation, repurchase 1,000 $3.700 Feb 04/08 Feb 01/08 BioMS Medical Corp. Direct Ownership Common Shares Class A 38 - Redemption, retraction, cancellation, repurchase 3,000 $3.680 Feb 04/08 Jan 31/08 BioMS Medical Corp. Direct Ownership Common Shares Class A 38 - Redemption, retraction, cancellation, repurchase 3,000 $3.750 [Amended Filing] - Amended Filing

By analyst8

Posted: Thursday Jan 10 3:14:38PM 2008

Good signs .. insiders buying (CFO and VP Clinical Affairs) BioMS Medical Corp. (MS) As of January 9th, 2008 Filing Date Transaction Date Insider Name Ownership Type Securities Nature of transaction # or value acquired or disposed of Unit Price Jan 09/08 Jan 07/08 Kimak, Donald William Direct Ownership Common Shares Class A 10 - Acquisition in the public market 3,500 $3.750 Jan 09/08 Jan 07/08 Kimak, Donald William Direct Ownership Common Shares Class A 10 - Acquisition in the public market 5,000 $3.770 Jan 03/08 Dec 26/07 Arfors, Leopold Bernt Harry Direct Ownership Common Shares Class A 10 - Acquisition in the public market 18,000 $3.765 Dec 21/07 Dec 20/07 Kimak, Donald William Indirect Ownership Common Shares Class A 90 - Change in the nature of ownership -2,000 Dec 21/07 Dec 20/07 Kimak, Donald William Direct Ownership Common Shares Class A 10 - Acquisition in the public market 6,000 $3.600 Dec 21/07 Dec 20/07 Kimak, Donald William Direct Ownership Common Shares Class A 90 - Change in the nature of ownership 2,000 Nov 05/07 Oct 24/07 Arfors, Leopold Bernt Harry Direct Ownership Common Shares Class A 10 - Acquisition in the public market 34,000 $2.883

By analyst8

Posted: Tuesday Jan 8 9:13:39AM 2008

Versant Report .. with $12 target price. BIOMS MEDICAL CORPORATION Attractive MS drug MBP8298 poised to generate interim pivotal data by mid-2008 Recommendation: BUY Symbol: MS Exchange: TSX Sector: Healthcare & Biotechnology All dollar values in C$ unless otherwise noted. Current price: $3.88 One-year target: $12.25 Dividend/dividend yield: NA Target return: 216% Financial summary Full-dil shares out. (M) 122.4 52-week high/low $4.39 / $1.70 Float (M) 82.7 Average volume 54,598 Market cap ($M) $471.3 Fiscal year end Dec 31 Float value ($M) $318.5 ($ million) 2009E 2010E 2011E 2012E MBP8298 royalty revenue $6.4 $80.4 $177.0 $321.8 R&D milestones and other $68.3 $68.3 $68.3 $68.3 Total revenue $74.8 $148.8 $245.3 $390.1 R&D expense $35.0 $25.0 $12.0 $12.0 Net income $33.7 $106.6 $147.7 $241.8 Fully taxed EPS $0.18 $0.63 $1.21 $1.98 % EPS growth (18%) 249% 93% 64% Source: Versant Partners BioMS is one of our Top Picks in 2008, and is up 62% since we initiated coverage in Mar/06. The company’s lead peptide drug MBP8298, is the most advanced secondary progressive multiple sclerosis (SPMS) therapy in development, targeting a multibillion dollar market opportunity with essentially no competitors on the horizon. With interim pivotal data from MBP8298 in SPMS that our model assumes will be positive expected in mid-2008, we expect significant share price appreciation for MS in 2008. Major valuation inflection point expected by midyear. As stated, we expect BioMS to report two-year efficacy data from the first 200-patients enrolled in its 611-patient pivotal Phase III Canadian/European SPMS trial (MAESTRO-01) by mid-2008 with final data from the remaining patients expected in Q1/09. We believe interim data will be positive based on already-reported Phase II data from a 32-patient study. There are no effective approved therapies for SPMS, so standard for approval is for MBP8298 to demonstrate reduced time-to-worsening of disease symptoms compared to placebo only, moderating clinical risk for the study. We are equally encouraged that a genetically defined patient subset exhibiting HLA-DR2 and HLA-DR4 haplotypes comprise most of the patients enrolled in the Phase III trial and were most responsive to therapy in the Phase II trial.). Interim data from MAESTRO-01 reduces clinical risk for U.S. pivotal study (MAESTRO-03). Not only is positive interim data from MAESTRO-01 a major valuation driver, but it also reduces risk for the company’s 510-patient U.S. pivotal study in SPMS, for which the FDA endorsed a similar study design to the Canadian/European study. Expect interim data from the U.S. study by Q4/09. SPMS represents an unmet medical need in a large market and Lilly clearly agrees. Recently consummated partnership for MPB8298 with pharma firm Eli Lilly for $87 million upfront, $410 million in milestones and royalties sales confirms our positive view on MBP8298’s medical potential. $0.00 $0.50 $1.00 $1.50 $2.00 $2.50 $3.00 $3.50 $4.00 $4.50 1/5/2007 3/2/2007 4/30/2007 6/26/2007 8/23/2007 10/22/2007 12/17/2007 Price (C$) - 500,000 1,000,000 1,500,000 2,000,000 2,500,000 3,000,000 3,500,000 4,000,000 4,500,000 5,000,000 Volume Douglas W. Loe, Ph. D., MBA Parimal Nathwani, MSc., MBA (Associate) dloe@versantpartners.com pnathwani@versantpartners.com (416) 849-5005 (416) 849-5008 Company profile: BioMS is a Phase III biotechnology firm that is developing a peptide-based therapy called MBP8298 for secondary progressive multiple sclerosis.

By analyst8

Posted: Tuesday Jan 8 9:12:09AM 2008

Research Capital Reports .. with $10 target price. TECHNOLOGY – BIOTECHNOLOGY – MARIA LUCKEVICH BIOMS MEDICAL CORP. (MS - TSX: C$3 . 89 – SPECULATIVE BUY; TARGET: C$10. 0 0 ) 􀂃 BioMS’s lead drug MBP8298 is a potential mega-blockbuster: MBP8298 is in two phase III trials, and these are the only phase III trials in the world that are testing a treatment for progressive multiple sclerosis. If this drug is successful in significantly slowing disease progression, then it will address an unmet market need, with revenue potential of $10 billion. Furthermore, over half of this market opportunity is in indications that have no current competitive drugs or drugs near market entry (there are four types of MS, and each one is a separate indication for regulatory purposes). 􀂃 MBP8298 has a big pharma partner: BioMS recently licensed MBP8298 to Eli Lilly in one of the largest licensing deals in Canadian biotech history, worth up to $497 million plus royalties. With an upfront payment of $87 million, BioMS is one of the few Canadian biotechnology companies that has no need for cash in the foreseeable future. The licensing deal also brings validation for the technology and the clinical program, provides a powerful partner that will interface with all regulatory agencies, and removes any uncertainty with respect to the ability of the collaborators to effectively commercialize the drug if they are to gain approval. 􀂃 BioMS is undervalued, and with two big milestones coming in 2008, may have its best year ever: Given the poor valuations that we are seeing in the Canadian biotechnology industry, we have been particularly conservative in our modeling, and yet we still arrive firmly at a $10.00 target price. BioMS’s upcoming milestones may be the catalyst(s) required to get the stock to that level; the milestones are a phase III interim analysis in mid-2008 and final data from a phase II trial in Q4/08. In the near term, a significant number of $4.00 warrants outstanding may weigh on the stock price.

By analyst8

Posted: Tuesday Dec 18 9:49:36AM 2007

Up 48% to $4.00 this morning on over 2.8M shares. I think there will be some fund managers doing some window dressing to try to add some of these into their portfolios before the month ends.

Canadian Small Caps

 
Canadian Small Caps

CLICK HERE to view the presentations from the Spring 2016 Small-Cap Conferences.

We are pleased to publish the PowerPoint presentations from The Small-Cap Conferences that were held in Calgary on March 30, 2016 and in Vancouver on May 3, 2016.

We encourage investors to review the presentations and contact the companies with any further questions.

www.smallcapconference.ca/presentations.php
plus

What's New